APA (7th ed.) Citation

Tang, B., Yan, X., Sheng, X., Si, L., Cui, C., Kong, Y., . . . Guo, J. (2019). Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients. Journal of hematology and oncology, 12(1), 7-15. https://doi.org/10.1186/s13045-018-0693-2

Chicago Style (17th ed.) Citation

Tang, Bixia, et al. "Safety and Clinical Activity with an Anti-PD-1 Antibody JS001 in Advanced Melanoma or Urologic Cancer Patients." Journal of Hematology and Oncology 12, no. 1 (2019): 7-15. https://doi.org/10.1186/s13045-018-0693-2.

MLA (9th ed.) Citation

Tang, Bixia, et al. "Safety and Clinical Activity with an Anti-PD-1 Antibody JS001 in Advanced Melanoma or Urologic Cancer Patients." Journal of Hematology and Oncology, vol. 12, no. 1, 2019, pp. 7-15, https://doi.org/10.1186/s13045-018-0693-2.